0001104659-22-068079.txt : 20220603
0001104659-22-068079.hdr.sgml : 20220603
20220603160806
ACCESSION NUMBER: 0001104659-22-068079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220601
FILED AS OF DATE: 20220603
DATE AS OF CHANGE: 20220603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHNETTLER THOMAS P
CENTRAL INDEX KEY: 0001271857
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40344
FILM NUMBER: 22994412
MAIL ADDRESS:
STREET 1: 800 NICOLLET MALL
STREET 2: J1012057
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55402-7020
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akoya Biosciences, Inc.
CENTRAL INDEX KEY: 0001711933
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 475586242
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE
STREET 2: 6TH FLOOR
CITY: MARLBOROUGH
STATE: MA
ZIP: 01762
BUSINESS PHONE: 855.896.8401
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE
STREET 2: 6TH FLOOR
CITY: MARLBOROUGH
STATE: MA
ZIP: 01762
4
1
tm2217652-7_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-06-01
0
0001711933
Akoya Biosciences, Inc.
AKYA
0001271857
SCHNETTLER THOMAS P
100 CAMPUS DRIVE,6TH FLOOR
MARLBOROUGH
MA
01762
1
0
0
0
Common Stock
2813771
I
Held by Piper Sandler Merchant Banking Fund II, L.P.
Stock Option (Right to Buy
11.24
2022-06-01
4
A
0
30549
0.00
A
2032-06-01
Common Stock
30549
30549
D
PSC Capital Management II LLC is the general partner of Piper Sandler Merchant Banking Fund II, L.P. Piper Sandler Companies is the manager of PSC Capital Management II LLC. The reporting person is the Co-CEO of PSC Capital Management II LLC and disclaims beneficial ownership of the shares held by Piper Sandler Merchant Banking Fund II, L.P.
Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023 or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.
/s/ Thomas P. Schnettler, by Brian McKelligon, as Attorney-in-Fact
2022-06-03